Role of anti vascular endothelial growth factor (VEGF) in ophthalmology
Keywords:VEGF, Bevacizumab, Lucentis, BRVO, CRVO
Vascular endothelial growth factor (VEGF), is a naturally occurring signal protein which is proinflammatory, stimulates angiogenesis and potent inducer of vascular permeability. Its role in normal physiology includes in embryonic development, wound healing and bone repair, neovascularization following MI and demonstrated in brain, kidney and GI mucosa. VEGF is responsible for many retinal diseases by causing new vessel growth and by increasing leakage and causing retinal swelling. Their use in ophthalmology includes in both anterior and posterior segment pathologies. This article explains the role of VEGFs, their mechanism of action, anti VEGFs, classification, their use, various studies and other aspects.
Claesson-Welsh L. VEGF-B taken to our hearts: specific effect of VEGF-B in myocardial ischemia. Arterioscler Thromb Vasc Biol. 2008;28:1575-1576.
Cébe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A, et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell Mol Life Sci. 2006 Sep;63(17):2067-77.
Shin YJ, Choi JS, et al. Induction of vascular endothelial growth factor receptor-3 mRNA in glial cells following focal cerebral ischemia in rats. J Neuroimmunol 2010;229(1- 2):81-90.
Robinson GS, et al. Neovascular role for VEGF. FASEB J 2001;15:1215-1217.
Holmes, Katherine; Roberts, Owain Ll; Thomas, Angharad M.; Cross, Michael J. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling 2007;19 (10):2003-12.
Kim I, Ryan R, et al. Consecutive expression of VEGF, VEGFR-1,VEGFR-2. Invest ophthalmol vis sci 1999;40:2115-2121.
Yang CM, Yeh PT, Chen MS (2008), Bevacizumab pretreatment and long acting gas infusion on vitreous clear uo after diabetic vitrectomy, Am J Ophthal,146:211-217.
Rizzo S, Genovesi- Ebert f, Williams G et al (2008), injection of intravitreal avastin as a preoperative adjunct before vitrectomy surgery in the treatment of severe PDR, Graefes arch clinical exp ophthalmol,246:837-842.
The use of a VEGF inhibitor (Lucentis) in refractory macular edema due to Eales disease. http//clinicaltrials.gov//ct2/show/NCT00384449.
Mason JO, Albert MA,Vail R. Intravitreal bevacizumab for refractory pseudophakic cystoids macular edema. Retina 2006:26;356-357.
Sun Y et al.Elevated vascular endothelial growth factor levels in Coats disease, rapid response to pegaptanib sodium.Graefes arch clinical exp ophthalmol 2007;245:1387-88.
Erdurmus M, Totan Y. Subconjunctival bevasizumab for corneal neovascularization . Graefes arch clinical exp ophthalmol 2007;245:1577-1579.
Sang Woo kim et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008, 115:e33-e38.
Kahook MY. Bleb morphology and vascularity after trabeculectomy with intravitreal bevacizumab.Am j ophthal,2010:150(3);399-403.
Rosenfeld et al for the MARINA study group. Ranibizumab for neovascular age related macular degeneration. N Eng J Medicine 2006:355;1419-1431.
Matsumoto Y, Bailey KF,Yanuzzi LA. Rebound macular edema following bevacizumab therapy for retinal venous occlusive disease. Retina 2007:27;426-431.
Alomar TS, Al-Aqaba M, Gray T, Lowe J, Dua HS. Histological and confocal microscopy changes in chronic corneal edema: implications for endothelial transplantation. Invest Ophthalmol Vis Sci. 2011 Oct 17;52(11):8193-207.
Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999 Sep-Oct;27(5):536-44.
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005 Jul-Aug;36(4):331-5.
Csaky KG, et al. Invest Ophthalmol Vis Sci. 2007;48:ARVO E-Abstract 4936.